MaaT Pharma Announces Resignation of an Independent Board Member

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer announced today the resignation of Mrs. Martine George from her position as member of the Board of Directors for personal reasons, with effect from June 1st, 2022. Her mandate will therefore not be renewed at the Annual General Meeting scheduled on May 31st, 2022.

The Board of Directors of the Company would like to thank Mrs. George for her contribution to the Board throughout her time in office. Starting June 1st, 2022, the Board of Directors will be composed of 6 members, including 3 independent members, and will be looking to fill the open position with a member that meets the development needs of MaaT Pharma.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, a Phase 3 clinical trial for patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, supports the development and expansion of its pipeline by determining novel disease targets, evaluating drug candidates, and identifying biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice.

MaaT Pharma is the first company developing microbiome-based therapies listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006158/en/

MaaT Pharma – Investor Relations Hervé AFFAGARD Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00 invest@maat-pharma.com

MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 07 55 25 36 prichaud@maat-pharma.com

Trophic Communications – Corporate and Medical Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89 2070 89831 maat@trophic.eu

Maat Pharma (EU:MAAT)
過去株価チャート
から 9 2024 まで 10 2024